Neptune Wellness Solutions Inc (NEPT)

[kookiekook]

NEPT - Neptune Technologies and Bioresources - $1.71 (down from ~$2.50 since Monday)

Pending Catalyst - Completion of 2 Phase II Studies for CaPre during the 1st quarter of 2013. Planned Phase III sudy for CaPre by end of 2013

CaPre is a Krill Oil derivative intended for the control of Tirglycerides, HDL and LDL Choresterol (The medical condition referred to as Hyperlipidemia). Results released so far show no safety concerns and reduction of triglycerides of 25%.

Potential Market - approximately 63 million adults in US suffer from high triglycerides levels.

Competition
Lovaza (a GSK drug). Lovaza has annual sales exceeding $700 Million annaully. Yearly prescription cost average $2300

Generic Lovaza - None available at this time but may become availalbe during 2013

Over-the-Counter Fish Oil Supplements - Fish Oil supplements with 1g of Oemga 3 are becoming more available and can produce results similiar to Lovaza, The cost for a year supply is about $200.


My Conclusions:
Unless there is a substantially better result CaPre will be could wind up being approved but only find a limited market as a prescription drug unless it can marketed at a low price or it tested against existing treatments and shows a substantial improvement.